Celularity Inc. — Earnings
Most recent reported period: FY2025 (Q3) (filed for period ending 2025-09-30) · sourced from SEC EDGAR
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-09-30 | $5M | ↓-43.2% | $-23M | ↓-43.3% | -244.1% |
| 2025-06-30 | $6M | ↓-52.6% | $-25M | ↓-278.0% | -276.6% |
| 2025-03-31 | $11M | ↓-22.2% | $-20M | ↑+10.3% | -91.8% |
| 2024-12-31 | $18M | ↑+49.7% | — | — | — |
| 2024-09-30 | $9M | ↑+145.5% | $-16M | ↑+82.9% | -124.0% |
| 2024-06-30 | $12M | ↑+312.2% | $-6M | ↑+86.5% | -84.0% |
| 2024-03-31 | $15M | ↑+273.1% | $-22M | ↑+65.6% | -50.2% |
| 2023-12-31 | $12M | ↑+193.3% | — | — | — |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q3)
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Margin trends · 28 quarters
margin trajectory tells the operating-leverage storyGo deeper
CELU Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyCELU Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics